Fluorothymidine F-18 PET in Diagnosing Patients With Intermediate or High Grade Soft Tissue Sarcoma

NCT ID: NCT03613259

Last Updated: 2020-06-09

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: EARLY_PHASE1
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-06-01
• Study Completion Date: 2022-06-01

Brief Summary

This pilot early phase I trial studies how well fluorothymidine F-18 positron emission tomography (PET) works in imaging patients with intermediate or high grade soft tissue sarcoma. Fluorothymidine F-18 PET may provide useful information about the tumor's response to treatment and may give the doctors early results that would better help to plan the post-surgical therapy.

Detailed Description

PRIMARY OBJECTIVES:

I. To determine fluorothymidine F-18 (¹⁸F-FLT) uptake parameters before and after radiotherapy.

SECONDARY OBJECTIVES:

I. To correlate ¹⁸F-FLT uptake post-radiotherapy scan with pathologic response. II. To correlate levels the mitotic index in surgical specimens with the ¹⁸F-FLT uptake in post-radiation scans.

III. To correlate ¹⁸F-FLT uptake both pre- and post-radiotherapy with magnetic resonance imaging (MRI) enhancement both within and around the tumor.

TERTIARY OBJECTIVES:

I. To compare ¹⁸F-FLT uptake and fludeoxyglucose F-18 (FDG) uptake when FDG-PET-computed tomography (CT) is available, pre-radiation, post-radiation, or both.

II. To compare ¹⁸F-FLT uptake in post-radiation scans with local recurrences looking for spatial correlation.

OUTLINE:

Patients receive fluorothymidine F-18 intravenously (IV) over 1 minute and undergo PET scan over 60 minutes 21 or less days prior to standard of care radiation therapy and 14 or less days prior to the standard of care surgery.

After completion of study, patients are followed up for 2 years.

Conditions

Stage II Adult Soft Tissue Sarcoma; Stage IIA Adult Soft Tissue Sarcoma; Stage IIB Adult Soft Tissue Sarcoma; Stage IIC Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Diagnostic (fluorothymidine F-18 PET)

Patients receive fluorothymidine F-18 IV over 1 minute and undergo PET scan over 60 minutes 21 or less days prior to standard of care radiation therapy and 14 or less days prior to the standard of care surgery.

Group Type: EXPERIMENTAL

Fluorothymidine F-18

Intervention Type: DRUG

Given IV

Laboratory Biomarker Analysis

Intervention Type: OTHER

Correlative studies

Positron Emission Tomography

Intervention Type: PROCEDURE

Undergo fluorothymidine F-18 PET

Interventions

Fluorothymidine F-18

Given IV

Intervention Type: DRUG

Laboratory Biomarker Analysis

Correlative studies

Intervention Type: OTHER

Positron Emission Tomography

Undergo fluorothymidine F-18 PET

Intervention Type: PROCEDURE

Other Intervention Names

¹⁸F-FLT; 3'-deoxy-3'-(¹⁸F) fluorothymidine; 3'-deoxy-3'-[¹⁸F]fluorothymidine; fluorothymidine F 18; Medical Imaging, Positron Emission Tomography; PET; PET Scan; positron emission tomography scan; Positron-Emission Tomography; proton magnetic resonance spectroscopic imaging

Eligibility Criteria

Inclusion Criteria

• Participants must have histological evidence of an intermediate or high grade soft tissue sarcoma (STS) of any stage
• Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as >= 1 cm with CT scan or MRI
• Prior resection is allowed if there is measurable gross disease and the subject plans to have neoadjuvant radiotherapy followed by resection
• Eastern Cooperative Oncology Group (ECOG) performance status =< 4, Karnofsky performance status >= 40%
• Creatinine =< 3 x upper limit of normal (ULM)
• Blood urea nitrogen (BUN) =< 3 x ULN
• Participants should be willing and able to have both PET-CT scans
• Participants should be eligible for and plan to undergo neoadjuvant radiation therapy and should be seen by a radiation oncologist prior to beginning the study; radiation at an outside facility will be allowed
• Participants should be eligible for and plan to have resection with a surgeon specializing in STS at Oregon Health and Science University (OHSU) and should be seen by said surgeon prior to beginning the study
• Participants should have a life expectancy that is greater than the study duration
• Participants should be willing to use adequate contraception from the time of the first PET-CT scan to 2 months after radiotherapy finishes; should a woman become pregnant while participating in this study, she should inform her treating physician immediately
• Women with childbearing potential must have a negative pregnancy test before each PET-CT scan
• Participants should have the ability to understand and the willingness to sign a written informed consent document
• Participants must sign a study specific consent form prior to registration

Exclusion Criteria

• Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or significant inflammation at treatment site or psychiatric illness/social situations that would limit compliance with study requirements or whose lab values do not meet the criteria above are excluded
• Pregnant women are excluded from this study
• Breast feeding women are excluded from this study
• Patients receiving chemotherapy during the course of radiation are excluded
• Patients whose weights exceed the tolerance of the table are excluded; the weight limit at OHSU is 450 pounds (lbs)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

OHSU Knight Cancer Institute

OTHER

Sponsor Role: lead

Responsible Party

Arthur Hung

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Arthur Y Hung, MD

Role: PRINCIPAL_INVESTIGATOR

OHSU Knight Cancer Institute

Other Identifiers

NCI-2017-00833

Identifier Type: REGISTRY

Identifier Source: secondary_id

SOL-16169-LX

Identifier Type: -

Identifier Source: secondary_id

STUDY00016373

Identifier Type: OTHER

Identifier Source: secondary_id

P01CA042045

Identifier Type: NIH

Identifier Source: secondary_id

View Link

P30CA069533

Identifier Type: NIH

Identifier Source: secondary_id

View Link

STUDY00016373

Identifier Type: -

Identifier Source: org_study_id